YM BioSciences (YMI) surges 21.9% AH after reporting positive results for the Phase I/II study...

|By:, SA News Editor

YM BioSciences (YMI) surges 21.9% AH after reporting positive results for the Phase I/II study of its CYT387 drug for treating myleofibrosis, both with regards to efficacy and safety. The company hopes to start "pivotal trials" for the drug in mid-2012.